Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavituximab with Paclitaxel/Carboplatin in Untreated Non-Squamous NSCLC
NCT01160601Phase 2Completed
- Sponsor
- Avid Bioservices, Inc.
- Start
- Jun 2010
- Primary completion
- Jun 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of bavituximab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Avid Bioservices, Inc. Primary endpoint: Objective Response Rate. Started Jun 2010; status: completed.
02
Drugs
bavituximab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01160601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01160601.